Numinus Wellness received final approval from the Toronto Stock Exchange to graduate its listing to the TSX from the TSX-Venture Exchange.
Numinus Wellness‘ common shares began trading on the TSX under the symbol NUMI on December 16, 2021, and rang the opening bell to celebrate the milestone.
Numinus Founder and CEO, Payton Nyquvest, who was joined by members of Numinus’ senior management team at the event, spoke to Psychedelic Health to say: “I’m proud of what Numinus has achieved over the past three years by staying true to our mission of providing accessible and innovative care and focusing on being in service to all in need.
“Graduating to the TSX is an important milestone for Numinus as we take key steps to heighten our corporate profile and reach a broader range of investors.
“This up-listing is another indication that Numinus has effectively advanced our healthcare strategy, met our business objectives, and built a rapidly scalable growth platform to lead the emerging sector of psychedelic-assisted psychotherapy.
“This is also reflective of many exciting developments occurring at Numinus. We’re actively growing our clinic network across North America, expanding our lab capabilities, and strategically investing in clinical research to drive long-term value creation for our investors.
“This is only the beginning of our journey, and we look forward to continuing to champion our mission in this industry.”
The company will be trading on the TSX under the symbols NUMI.WT, NUMI.WT.B and NUMI.WT.C.
[activecampaign form=52]
